Full-Time

Field Service Support Engineer 2

Intuitive Surgical

Intuitive Surgical

10,001+ employees

Manufactures robotic surgical systems and services

No salary listed

Phoenix, AZ, USA

In Person

Must reside within 30 miles of an airport; up to ~80% travel within territory.

Category
Hardware Engineering (1)
Required Skills
Inventory Management

People at Intuitive Surgical

People at Intuitive Surgical who can refer or advise you

Requirements
  • 1-3 years of Field Service Experience preferred
  • Associate’s degree in related field or equivalent training/experience preferred
  • Proven track record of troubleshooting electro-mechanical systems preferred
  • Good written and oral communication skills
  • General computer skills
  • Strong administrative and record keeping skills
  • Clean driving record
  • Able to lift 75 lbs and move wheeled objects up to 1200 lbs
  • Current proof of vaccination may be required by Intuitive and/or customers (COVID-19) as applicable to role
Responsibilities
  • Perform all types of scheduled maintenance activities for an assigned territory including, but not limited to; system inspections, preventive maintenance, software updates, system recalls, field actions, and upgrades
  • Troubleshoot, diagnose, and repair all Intuitive products and associated equipment within a specified territory or region in accordance with procedures and within designated timeframes
  • Coordinate and perform system and hardware delivery and installation
  • Competent in knowledge and implementation of OR protocol and HIPAA standards
  • Complete all administrative duties including, but not limited to; Spare parts inventory, Field Activity Reports, Return Material Authorizations, Expense Reports etc. within the prescribed timeframes
  • Maintain all Intuitive provided items to include: issued tooling, calibrated tool sets, employee vehicle, laptops, iPads, and any other company owned or issued assets
  • Support Intuitive teams as required to facilitate company objectives; eg. Assist outside territories during times of an open territory or during absence of assigned Field Service Engineer, assist Sales teams with trade show support as required, assist Genesis teams with sterile reprocessing training as required, provide hospital contacts to other Intuitive teams as required, etc.
  • Provide feedback to HQ and take part in continuous improvement projects as required to improve processes and find efficiencies
  • Complete all required training items to include, but not limited to; equipment training for all Intuitive products you may need to support, Intuitive Surgical University classes as required, and professional development courses as required by management
  • Maintain all aspects of a temporarily assigned territory or region to include, but not limited to; responding to customer needs, establishing a rapport with assigned customer base, and supporting customer training and events as required
  • Conduct training sessions at ISI, training centers, and hospitals
  • Understand and comply with all department and company policies
  • Provide management with a quarterly territory review and assessment
  • Complete all administrative tasks in the required time frame
  • Ability to Travel ~80% within the travel and expense policy
  • Ad hoc tasks assigned by management
  • Reside within 30 miles of an airport and within a designated city in your assigned region
  • Willing to work a flex shift, second shift, or other as required by territory and management
  • Demonstrate individual characteristics expected of Intuitive personnel (e.g. Character, capacity, energy, experience)
Desired Qualifications
  • 1-3 years of Field Service Experience preferred
  • Associate’s degree in related field or equivalent training/experience preferred
  • Proven track record of troubleshooting electro-mechanical systems preferred

Intuitive Surgical designs, manufactures, and sells robotic surgical systems and provides related services and accessories for minimally invasive surgery. The core product helps surgeons perform operations with enhanced precision by guiding robotic arms controlled from a console, allowing procedures to be done through small incisions. Instruments and consumables are used with the systems and are supported by service contracts, creating a recurring revenue stream. Compared to competitors, Intuitive has a large installed base and focuses specifically on robotic-assisted surgery, combining devices, disposable instruments, and ongoing services to support hospitals and surgical centers. Its goal is to improve patient outcomes by enabling safer, less invasive procedures while expanding the use and capabilities of robotic surgery for more procedures and providers.

Company Size

10,001+

Company Stage

IPO

Headquarters

Sunnyvale, California

Founded

1995

People at Intuitive Surgical

People at Intuitive Surgical who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Ion procedures surged 39% in Q1, driving combined growth to 17%.
  • CE Mark approval for da Vinci 5 in Europe enables expanded pediatric use.
  • AI-driven telepresence and mobile login upgrades strengthen global commercial execution.

What critics are saying

  • Medtronic Hugo erodes da Vinci share in general surgery with aggressive pricing.
  • FDA delays for cardiac and SP applications stall 15% growth forecast.
  • All-in-one AI platform with no instrument costs could obsolete recurring revenue model.

What makes Intuitive Surgical unique

  • da Vinci 5 dominates robotic surgery with 99% uptime and Force Gauge visualization.
  • Intuitive pioneered minimally invasive care with 30 years of robotic technology expertise.
  • Extended instrument lifespans to 15 uses reduce bottlenecks without cutting revenue.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Hybrid Work Options

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Yahoo Finance
Apr 7th, 2026
Intuitive Surgical emerges as dark horse in anti-obesity market as surgery outperforms GLP-1 drugs

Intuitive Surgical could emerge as a dark horse in the anti-obesity market as bariatric surgery proves more effective than GLP-1 drugs for long-term weight loss. A recent study of over 50,000 patients found surgery patients lost an average of 58 pounds after two years, compared to just 12 pounds for those using GLP-1 medications. The study also showed surgery delivers more sustainable results. Gastric bypass patients maintain around 52% of their excess weight loss after 10 years, whilst GLP-1 users often regain all lost weight after stopping treatment. Intuitive's da Vinci surgical system offers minimally invasive bariatric surgery options. The company generated $10.1 billion in revenue last year, up from $8.4 billion, with profit margins around 28%. Despite shares falling over 20% this year, the company's position in surgical innovation makes it a compelling long-term investment.

Yahoo Finance
Mar 29th, 2026
Intuitive Surgical shares drop 19% YTD, but analysts see 15% upside potential

Intuitive Surgical has experienced recent share price weakness, declining 3% in one day with negative returns over the past week, month and three months. The stock currently trades at $452.66, down 10.1% over one month and 19.45% year-to-date, though three-year total shareholder returns remain strong at 77.19%. The medical technology company reports annual revenue of $10.1 billion and net income of $2.9 billion, maintaining a dominant position in minimally invasive surgical technology. According to one valuation analysis, Intuitive Surgical's fair value sits at $532.46, suggesting the stock is undervalued by approximately 15% at current levels. The analysis projects 12% annual revenue growth over the next five years, supported by recurring revenues from spare parts and software licences, with profit margins expected to reach 30% from the current 28.6%.

Yahoo Finance
Mar 28th, 2026
Intuitive Surgical shares up 23% after Jim Cramer's buy recommendation

Intuitive Surgical shares rose 23% following Jim Cramer's recommendation on CNBC's Squawk on the Street in June 2025, where he urged investors to "just go buy ISRG". The medical robotics company experienced a 27% surge in October after reporting third-quarter earnings that beat analyst estimates. Revenue reached $2.51 billion against expectations of $2.40 billion, whilst adjusted earnings per share hit $2.40 versus the predicted $1.98. However, the stock declined 2.7% in January 2026 after Intuitive Surgical released preliminary fourth-quarter results, citing concerns that Medicaid funding cuts and competing products could slow growth of its robotic surgical systems. Despite the recent setback, shares remain up significantly since Cramer's initial endorsement, though they're down 7.8% over the past year.

Yahoo Finance
Mar 28th, 2026
Intuitive Surgical faces tariff headwinds and rising competition despite 19% revenue growth to $2.87B

Intuitive Surgical faces headwinds from tariffs and increased competition in the robotic-assisted surgery market, yet its fundamentals remain strong. The medical device company reported fourth-quarter revenue growth of 19% to $2.87 billion, whilst adjusted earnings per share rose 14.5% to $2.53. Procedures using its da Vinci surgical system increased 17%, with the installed base growing 12% to 11,106 units. However, the stock trades at 47.6 times forward earnings, compared to the healthcare sector average of 17.1. New competition is emerging, with Medtronic's Hugo system recently cleared and Johnson & Johnson expected to launch its own device soon. Despite these challenges, Intuitive Surgical maintains advantages through switching costs and extensive real-world data, whilst the underpenetrated robotic-assisted surgery market offers long-term growth potential.

Yahoo Finance
Mar 24th, 2026
ISRG maintains 37% operating margins in Q4 despite 95 bps tariff drag

Intuitive Surgical maintained a 37% operating margin in Q4 despite tariffs creating a 95 basis point drag, alongside higher facility costs and unfavourable product mix from newer platforms like da Vinci 5 and Ion. The company offset these pressures through product cost reductions, component savings and manufacturing efficiencies. Procedure growth of 18% in Q4 and recurring revenue now comprising 81% of total revenues provided operating leverage. Management's 2026 gross margin guidance of 67-68% suggests continued stability, even as tariff headwinds are expected to increase to roughly 1.2% of revenues. Meanwhile, Boston Scientific expanded adjusted operating margins by 100 basis points to 28% in 2025, though tariffs will offset favourable product mix in 2026. The company expects 50-75 basis points operating margin expansion in 2026 through scale efficiencies and supply-chain optimisation.